A medication that has sat in medicine cabinets for decades as a constipation remedy may have a far more significant role to play: slowing the relentless decline of kidney function in people with chronic disease.
Researchers at Tohoku University uncovered the connection after noticing a pattern. Constipation frequently accompanies chronic kidney disease, and they wondered whether treating one problem might help the other. The hypothesis led to a clinical trial that tested lubiprostone, a drug long approved for constipation, in patients with moderate kidney disease.
The results were striking enough to shift how scientists think about kidney protection. Patients who received lubiprostone showed measurably slower decline in kidney function over 24 weeks compared with those given a placebo. The effect appeared stronger at higher doses, with the 16 microgram dose showing the most promise when measured by estimated glomerular filtration rate, the standard metric for kidney health.
The trial enrolled 150 patients across nine Japanese medical centers. That the findings emerged from a Phase 2 study means the results are preliminary, but they open a door that researchers had only begun to unlock through animal studies.
The Gut Holds the Secret
Why would a constipation drug help kidneys? The answer lies in a concept increasingly central to medicine: the gut-kidney axis, the intricate relationship between intestinal bacteria and kidney health.
Lubiprostone appears to reshape the microbiome in a way that benefits kidney cells at the molecular level. The drug increased production of spermidine, a compound that enhances mitochondrial function. Mitochondria are the cellular power generators, and when they work better, cells throughout the body sustain less damage.
The researchers found that kidney tissue may be particularly vulnerable to mitochondrial decline. By bolstering these cellular engines through microbiome changes, the treatment seemed to shield kidneys from further deterioration. The mechanism does not rely on reducing uremic toxins in the way scientists initially expected, but rather on fundamental cellular energy production and bacterial composition shifts.
Chronic kidney disease affects hundreds of millions of people worldwide and drives millions toward dialysis each year. Current treatments slow progression but do not restore lost kidney function. The urgency of finding new approaches is undeniable.
What makes this finding especially practical is that lubiprostone already carries FDA approval. Unlike a novel molecule that would require years of development and regulatory review, this drug could theoretically move into larger trials and eventual clinical use far more quickly if Phase 3 studies confirm the benefits.
Researchers are now designing those larger confirmatory trials and investigating which patients might benefit most. They are also exploring whether the same gut-focused strategy could help other chronic diseases rooted in mitochondrial dysfunction.
For kidney patients today, even modest slowing of decline matters enormously. It could delay the onset of dialysis by months or years, preserving quality of life and independence. The discovery represents a genuine shift in thinking, from viewing constipation and kidney disease as separate problems to understanding them as symptoms of a deeper biological imbalance that may be addressable through a single intervention.
Author Jessica Williams: "If a 30-year-old constipation drug can slow kidney disease in humans, we've been sitting on kidney medicine this whole time without knowing it."
Comments